What is Immunome?
Immunome operates at the forefront of biopharmaceutical innovation, leveraging a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics. The company's strategic focus is on addressing critical unmet needs in oncology and infectious diseases, including the development of treatments for COVID-19. By harnessing the power of memory B cells from patients who have naturally fought off diseases, Immunome's discovery engine aims to identify novel antibodies and their corresponding targets, positioning it as a key player in the advancement of disease treatment paradigms.
How much funding has Immunome raised?
Immunome has raised a total of $201.4M across 8 funding rounds:
Debt
$846K
Debt
$892K
Private Equity
$3.6M
Series A
$5M
Debt
$350K
Stock Offering
$39M
Share Placement
$27M
Share Placement
$124.7M
Debt (2010): $846K, investors not publicly disclosed
Debt (2014): $892K, investors not publicly disclosed
Private Equity (2015): $3.6M, investors not publicly disclosed
Series A (2016): $5M, investors not publicly disclosed
Debt (2020): $350K backed by PPP
Stock Issuance/Offering (2020): $39M, investors not publicly disclosed
Share Placement (2021): $27M, investors not publicly disclosed
Share Placement (2023): $124.7M, investors not publicly disclosed
What's next for Immunome?
The recent major strategic investment signals a significant milestone for Immunome, likely enabling the company to accelerate its research and development pipelines, expand its clinical trial capabilities, and potentially forge new strategic partnerships. This enterprise-level backing suggests confidence from investors in Immunome's innovative platform and its potential to deliver impactful therapeutic solutions. The company is poised to further solidify its position in the competitive biopharmaceutical landscape, driving forward its mission to transform disease treatment through advanced antibody discovery.
See full Immunome company page
